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ABSTRACT
Objective: This study was conducted to evaluate the use of genetic tests, before prescribing drugs to reduce not only the level of side effects but 
also the costs associated with changing therapy. In this paper, the authors analyze the economic efficiency of HLA*5701 prospective screening of 
hypersensitivity to abacavir (ABC) in the treatment of HIV-infected patients.
Methods: A retrospective study was conducted among HIV-infected patients taking first-line antiretroviral therapy and further, based on the results 
obtained with the ABC-hypersensitivity reactions, analyzed the costs that affect on healthcare system.
Results: In the study group of HIV-infected patients, most of the cases belonged to a young, socially active part of the population. Among the study 
population of patients (n=637), 171 patients were assigned ABC-containing antiretroviral therapy. An increase in costs was found in 67% of cases 
when ABC-containing first-line therapy was replaced due to the occurrence of undesirable reactions.
Conclusion: The results show that, using this screening, we could reduce the costs associated with replacement therapy.
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INTRODUCTION
Abacavir (ABC) is an antiretroviral drug belonging to the class of 
nucleoside reverse-transcriptase inhibitors [1]. It has proven effective in 
first-line antiretroviral therapy (ART) regimens [2]. However, one of the 
life-threatening side effects of antiretroviral drugs is the development of 
hypersensitivity reaction. There was a significant association between 
the development hypersensitivity reaction to ABC and the presence of 
the HLA-B*5701 allele. In this regard, it was recommended to include 
screening typing on the HLA-B* 5701 marker in routine clinical practice 
and to conduct it before the appointment of ABC [3].
Pharmacogenetic testing is not widely used in routine clinical practice 
to optimize the drug choice or clinical treatment [3]. This gap between 
scientific knowledge and clinical application can be explained by the 
fact that successful inclusion of the pharmacogenetic test in broad 
practice requires a combination of highly effective drugs and reliable 
laboratory tests with an effective strategy for including testing in a 
broad clinical practice.
Symptoms of hypersensitivity reactions to ABC include fever, 
rash, constitutional symptoms, gastrointestinal symptoms, and 
respiratory symptoms, which become more severe with the 
continued use of ABC. Immediate and permanent discontinuation of 
ABC is mandatory, leading to a rapid disappearance of symptoms. 
The subsequent readministration of ABC is contraindicated, as it 
may lead to a more serious, rapid, and potentially life-threatening 
reaction.
Studies have shown that adherence to ART raises the quality of life 
among HIV-infected patients, but lifelong adherence to therapy is 
required [4]. To ensure more safe and effective treatment of patients 
at all levels of the health system, continuous evaluation and monitoring 
of the harm and benefits of ART are required [5]. Conducting genetic 
screening is of interest not only from the standpoint of preventing the 
development of side effects but also to reduce the cost of therapy.
Thus, in a number of studies, it has been shown that prospective HLA-B* 
5701 screening before initiation of ABC therapy reduces the cost of 
therapy [6,7]. In a study using mathematical modeling, it was shown that 
the extensive use of HLA-B* 5701 screening before the administration of 
ABC to HIV-infected patients may result in cost savings or a small additional 
expenditure for the health system, which, however, is counterbalanced by 
a reduction in the incidence of side effects on ABC [7,8].
Based on data from a US-based study, the use of prospective HLA-B* 
5701 screening is effective in choosing to start antiretroviral therapy, 
with the $/QALY indicator (cost of 1 year of life with a quality of life 
corresponding to absolute health) of $ 50,000, which testifies to the 
marginal effectiveness. Nevertheless, the cost-effectiveness ratio largely 
depends on the effectiveness of therapy with regimens including ABC or 
alternative regimens including tenofovir, taking into account the cost of 
the drugs themselves and also taking into account the cost of carrying 
out the HLA-B* 5701 test itself [9-12].
To improve the effectiveness of treatment, a useful method was the 
economic evaluation in health research [13]. Thus, the question of the 
pharmacoeconomic efficiency of using the prospective HLA-B* 5701 
screening needs a deeper study, which determined the purpose and 
objectives of our study.
METHODS
To estimate the costs associated with ABC-hypersensitivity reactions, 
we performed a retrospective standardized assessment of clinical 
suspicious cases of them in the specific population and further, based 
on the results obtained with the ABC- hypersensitivity reactions, 
analyzed the costs that effect on health care system. The sources of 
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information were 637 case histories of patients with HIV infection. The 
main criterion for including patients in the cohort was the presence of 
an established diagnosis of HIV infection. The criteria for including of 
the second level were adopted:
•	 Age	over	18;
•	 Non-participation	in	clinical	trials	during	the	reviewed	period;
•	 The	 primary	 appointment	 of	 antiretroviral	 therapy,	 including	
ABC-containing therapy.
To estimate the costs associated with changing the starting ABC-
containing therapy to an alternative treatment regimen, we took into 
account the difference in their cost. To get this purpose, a summary 
table was compiled to reflect all substitutions of ABC-containing 
ART regimens for each patient in the study group, and cost changes 
were also assessed depending on the reason for the modification of 
therapy. This methodical approach allowed to estimate the share 
of each component in the cost structure for the change of ABC-
containing therapy and the further possibility to optimize this type 
of burden.
To estimate the costs associated with the use of the HLA-B* 5701 
test, the cost of it was carried out. The cost of two-, three-, or four-
component ART regimens was determined by adding the cost of each 
individual antiretroviral preparation in the treatment regimen over the 
same period of time.
RESULTS
Analysis of the epidemiological indicators of the population studied 
revealed the prevalence of men about 61% and 39% of women. 
Unsecured sex (of which, heterosexual 47.6% and homosexual 12.4%) 
was indicated as the main risk factor for infection in 60% of cases. 
Injecting drug use as the main risk factor for infection was observed 
in 24.5% of the study population. However, it should be noted that 
it is possible that not all patients openly reported injecting drug use 
(Table 1).
Thus, it can be concluded that, in the study group, the young, socially 
active part of the population was infected with HIV infection in most 
of the cases. Heterosexual sexual intercourse was noted as the most 
frequent route of infection.
During the pharmacoepidemiological study, it was found that 474 
people (74.4%) were prescribed starting ART, of which 171 patients had 
initiation therapy with ABC containing in a specific study population of 
HIV patients on dispensary observation (n=637 people).
Among the analyzed population, 5.5% of patients reported the 
development of adverse reactions after the appointment of starting 
ABC-containing therapy.
Analysis of substitution therapy showed that the greatest increase 
in cost was observed using combinations ritonavir (RTV)/presista 
and combivir (AZT/lamivudine [3TC]/issetress. The combination 
of ABC/3TC/atazanavir/RTV was not included in 10 most common 
regimens for initiation of ABC therapy, but most often caused side 
effects (11.5%). Perhaps, the multicomponent scheme of this scheme 
led to the development of side effects, which indicates that side effect 
can cause another drug.
When analyzing all ABC-containing start-up therapy regimens that 
included the replacement of the drug due to the occurrence of undesired 
reactions, a total increase in expenditure was found in 67% of cases on 
average by 54164.6 rubles.
At the same time, the cost of HLA-B* 5701 tests for patients who had 
to change ABC-containing therapy due to adverse reactions would be 
5201.3 rubles. Moreover, only 1 scheme of 26 cases was canceled due 
to the development of side effects, which corresponded to the clinical 
picture of ABC-hypersensitivity reactions (Table 2).
This indicates the pharmacoeconomic inefficiency of replacement 
therapy due to  ABC -associated undesirable side reactions.
DISCUSSION 
The results of our study serve as an additional rationale for the 
introduction of the HLA-B*5701 hypersensitivity test for ABC at the 
federal level to prevent inappropriate changes in therapy, not only 
clinically but also economically.
The data obtained are an additional justification for the need to 
strengthen measures to prevent side effects, including prospective 
HLA-B*5701 screenings before the appointment of ABC, which together 
will reduce the high costs of frequent replacement of ART.
Thus, this analysis shows the current significance of the HLA-B*5701 
hypersensitivity test for ABC, not only to provide quality pharmaceutical 
care to HIV-infected patients but also to reduce the costs associated 
with replacement therapy.
CONCLUSION
Antiretroviral therapy helps not only to prolong but also to improve the 
quality of life of HIV-infected patients. The pharmacoeconomic study of 
using genetic tests before the appointment of therapy has a huge impact 
on the rational use of drugs, reducing the development of side effects. 
This research has a great practical importance of controlling medical 
costs and reducing them not only for patients but also for a society.
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Not reported 147 (23.1)
Path of infection
Injecting drugs 156 (24.5)
Hetero 303 (47.6)
Homo 79 (12.4)
Homo, hetero 4 (0.6)
No data 84 (13.2)
Other 11 (1.7)
Table 2: The scheme was canceled due to the development of 
side effects, which corresponded to the clinical picture of the 
reaction of ABC hypersensitivity
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